Clinical Trials Directory

Trials / Completed

CompletedNCT02093065

Platelet Function in Patients With Hemophilia A

Decreased Platelet Function as a Cause of Increased Bleeding in Patients With Hemophilia A

Status
Completed
Phase
Study type
Observational
Enrollment
36 (actual)
Sponsor
Boston Children's Hospital · Academic / Other
Sex
Male
Age
2 Years – 18 Years
Healthy volunteers
Not accepted

Summary

Abnormalities in the gene encoding Factor VIII (FVIII) results in hemophilia A, an X-linked recessive bleeding disorder with a prevalence of 1 in 5000 males. Hemophilia A patients are classified into 3 different categories based on residual FVIII activity compared to normal: mild (6-40%), moderate (1-5%) and severe (\<1%). This categorization correlates to some degree with bleeding phenotype, but does not completely define it. Some patients with hemophilia A bleed less often than others despite identical plasma FVIII levels. The cause(s) of this phenotype heterogeneity in hemophilia A remains largely unknown, despite a number of studies of possible factors. Activated platelets, in addition to their role in primary hemostasis, play a major role in secondary hemostasis (coagulation) by providing a phospholipid surface to which coagulation factors bind. A role for platelets in the hemorrhagic propensity of hemophilia A has been suggested in the past, but only a small number of studies have been performed with limitations in assays performed and numbers of patients. The purpose of the present study is to determine whether platelet reactivity in severe hemophilia A patients is associated with past bleeding frequency and/or predicts future bleeding frequency.

Conditions

Timeline

Start date
2015-03-01
Primary completion
2018-06-01
Completion
2020-02-01
First posted
2014-03-20
Last updated
2020-07-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02093065. Inclusion in this directory is not an endorsement.